​

Mereo BioPharma Group (MREO) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

MREO Stock Forecast

Mereo BioPharma Group (MREO) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $6.75, with a high of $8.00 and a low of $4.00. This represents a 142.81% increase from the last price of $2.78.

$2 $3 $4 $5 $6 $7 $8 High: $8 Avg: $6.75 Low: $4 Last Closed Price: $2.78

MREO Stock Rating

Mereo BioPharma Group stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

MREO Price Target Upside V Benchmarks

TypeNameUpside
StockMereo BioPharma Group142.81%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$8.00
Last Closing Price$2.78$2.78$2.78
Upside/Downside--187.77%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2526---8
May, 2526---8
Apr, 2526---8
Mar, 2516---7
Feb, 2516---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 20, 2024Joseph SchwartzLeerink Partners$8.00$3.98101.01%187.77%
Jun 12, 2024Jack AllenRobert W. Baird$8.00$3.83108.88%187.77%
Jun 12, 2024Gil BlumNeedham$7.00$3.5298.86%151.80%
Mar 28, 2024Gil BlumNeedham$6.00$3.00100.00%115.83%
Aug 12, 2022Cantor Fitzgerald$4.00$1.35196.30%43.88%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 12, 2024NeedhamBuyBuyhold
Mar 28, 2024NeedhamBuyBuyhold
Aug 12, 2022Cantor FitzgeraldOverweightinitialise
Jun 06, 2022NeedhamBuyBuyhold
Mar 17, 2022NeedhamBuyBuyhold
Apr 05, 2021NeedhamBuyinitialise

Financial Forecast

EPS Forecast

$-250 $-170 $-90 $-10 $70 $150 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$149.93$-220.04$-0.06----
Avg Forecast$-0.05$-0.04$-0.05$-0.02$-0.03$-0.01$0.05
High Forecast$-0.05$-0.03$0.10$0.01$-0.03$0.06$0.05
Low Forecast$-0.05$-0.04$-0.10$-0.04$-0.03$-0.05$0.05
Surprise %-299960.00%550000.00%20.00%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$36.46M$10.00M-----
Avg Forecast$18.43M$6.79M$14.48M$28.64M$33.64M$48.98M$111.19M
High Forecast$18.43M$6.79M$14.48M$28.64M$33.92M$48.98M$111.19M
Low Forecast$18.43M$6.79M$14.48M$28.64M$33.36M$48.98M$111.19M
Surprise %97.90%47.37%-----

Net Income Forecast

$-100M $-60M $-20M $20M $60M $100M Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$12.72M$-29.47M$-43.25M----
Avg Forecast$-30.86M$-21.17M$-33.86M$-17.33M$-17.27M$9.23M$34.55M
High Forecast$-30.86M$-19.24M$64.74M$3.42M$-17.27M$41.86M$34.55M
Low Forecast$-30.86M$-23.09M$-64.74M$-23.92M$-17.27M$-31.89M$34.55M
Surprise %-141.24%39.21%27.74%----

MREO Forecast FAQ

Is Mereo BioPharma Group stock a buy?

Mereo BioPharma Group stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Mereo BioPharma Group is a favorable investment for most analysts.

What is Mereo BioPharma Group's price target?

Mereo BioPharma Group's price target, set by 5 Wall Street analysts, averages $6.75 over the next 12 months. The price target range spans from $4 at the low end to $8 at the high end, suggesting a potential 142.81% change from the previous closing price of $2.78.

How does Mereo BioPharma Group stock forecast compare to its benchmarks?

Mereo BioPharma Group's stock forecast shows a 142.81% upside, outperforming the average forecast for the healthcare stocks sector (24.81%) and outperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Mereo BioPharma Group over the past three months?

  • June 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Mereo BioPharma Group’s EPS forecast?

Mereo BioPharma Group's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.02, marking a -66.67% decrease from the reported $-0.06 in 2024. Estimates for the following years are $-0.03 in 2026, $-0.01 in 2027, and $0.05 in 2028.

What is Mereo BioPharma Group’s revenue forecast?

Mereo BioPharma Group's average annual revenue forecast for its fiscal year ending in December 2025 is $28.64M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $33.64M, followed by $48.98M for 2027, and $111.19M for 2028.

What is Mereo BioPharma Group’s net income forecast?

Mereo BioPharma Group's net income forecast for the fiscal year ending in December 2025 stands at $-17.333M, representing a -59.93% decrease from the reported $-43.253M in 2024. Projections indicate $-17.274M in 2026, $9.23M in 2027, and $34.55M in 2028.